Beauvericin and enniatins H, i and MK1688 are new potent inhibitors of human immunodeficiency virus type-1 integrase

52Citations
Citations of this article
31Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Some enniatins (ENs) reportedly exhibit antiretroviral activities in vivo. The potential inhibitory activities of cyclic hexadepsipeptides such as beauvericin (BEA) and ENs H, I and MK1688 were investigated in vitro against human immunodeficiency virus type-1 (HIV-1) integrase and Moloney murine leukemia virus reverse transcriptase. BEA, EN I and EN MK1688 exhibited strong inhibitory activities against HIV-1 integrase, whereas EN H showed relatively weak activity. None of the examined compounds showed anti-reverse transcriptase activity. BEA was the most effective inhibitor of the tested cyclic hexadepsipeptides in inhibiting HIV-1 integrase. These results indicate the potential of cyclic hexadepsipeptides as a new class of potent inhibitors of HIV-1 integrase. © 2009 Japan Antibiotics Research Association All rights reserved.

Cite

CITATION STYLE

APA

Shin, C. G., An, D. G., Song, H. H., & Lee, C. (2009). Beauvericin and enniatins H, i and MK1688 are new potent inhibitors of human immunodeficiency virus type-1 integrase. Journal of Antibiotics, 62(12), 687–690. https://doi.org/10.1038/ja.2009.102

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free